Kun Ming Shi

Researchers are evaluating the effects of a triple therapy inhaler combining budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with Chronic Obstructive Pulmonary Disease COPD who have a higher risk for heart and lung events. This Phase III study is randomized, double-blind, and conducted at multiple centers, focusing on participants with COPD and elevated cardiopulmonary risk. Participants will receive either the triple therapy inhaler or the dual therapy inhaler, both administered twice daily. The study compares these two inhalers over a period of up to three years, monitoring for serious cardiac or COPD events. The trial includes careful evaluation of various heart and lung-related health events during this period. During the study, participants will be closely monitored through regular visits, assessments, and tests to measure lung function, heart events, and COPD exacerbations. Researchers will track the time until the first severe cardiac or COPD event and evaluate other cardiovascular and respiratory outcomes over up to three years. Participants will also be assessed for their ability to properly use the inhaler and adherence to the study protocol throughout the trial.

Non-cystic fibrosis bronchiectasis NCFBE is a chronic lung disease marked by persistent cough with mucus and repeated lung infections, caused by permanent widening of the airways. This condition is increasingly common worldwide and poses significant health and economic challenges. Chinese patients with NCFBE show different clinical features compared to Western patients, including more frequent hospitalizations and different infection patterns, but the underlying biological causes remain unclear. This study will observe and analyze Chinese NCFBE patients and healthy adults using biomarker tests and advanced molecular analyses to explore how disease pathways relate to symptoms and uncover distinct molecular types behind clinical presentations. The study includes a group of healthy controls aged 30 or older and up to 300 NCFBE patients aged 18 or older, with about 30% having had at least two lung flare-ups in the past year. Healthy participants will be assessed mainly at the start and optionally with bronchoscopy, while patients will have baseline, 6-month, 12-month, and additional visits during flare-ups. Participants will attend scheduled visits for clinical assessments, lung function tests, imaging, sputum microbiology, and questionnaires over 12 months. Data collected include lung function measures, imaging results, gene expression, symptom scores, and medical history to help identify disease patterns. The study also allows phone visits for some follow-ups and tracks flare-up events and hospitalizations to better understand disease progression and patient outcomes.

This research aims to study the long-term effects of successfully removing Pseudomonas aeruginosa PA infections in adults with bronchiectasis. It builds on a previous trial called ERASE that tested inhaled Tobramycin to clear PA in patients newly diagnosed with this infection. The goal is to see if eradicating PA improves health outcomes over a longer period. The study involves an extended observation period totaling 36 months, combining the first 9 months from the initial ERASE trial with an additional 27 months of follow-up. Participants are grouped based on whether they successfully cleared PA in the prior study. There is no new treatment given during this follow-up phase it is an observational study tracking patients over time. Participants will be monitored regularly for quality of life, lung function, frequency and severity of lung flare-ups, hospital visits, and treatment costs. Researchers will also check sputum samples at various time points up to 36 months to detect any return of PA infection. This comprehensive follow-up will help understand the long-term benefits and challenges after PA eradication in bronchiectasis patients.

Researchers are evaluating benralizumab in patients aged 12 years and older with severe eosinophilic asthma to better understand its clinical profile and how well it works in a real-world setting in China. The study aims to observe early treatment responses, treatment outcomes, and changes in asthma control. It also looks at reasons why doctors may stop or switch benralizumab therapy. Participants receive benralizumab as prescribed by their clinician without any additional intervention from the study, as this is a non-interventional observational trial. The study collects data over time, focusing on asthma control and lung function. There is only one group of patients receiving benralizumab, and treatment decisions are made by healthcare providers as usual. Participants will be followed and monitored with asthma control questionnaires at weeks 1, 2, 4, 8, 16, 24, 40, and 56. Lung function changes will also be evaluated at weeks 8, 16, and 56. The primary outcome is asthma control at week 8. Data collection will continue until the study ends in January 2028, providing insights into treatment effects and patient experiences in routine care.